Speciality
Clinical Professor,Department of Clinical Oncology of The Chinese University of Hong Kong.

Personal Information

Prof. Stephen Lam CHAN is the Clinical Professor at the Department of Clinical Oncology of the Chinese University of Hong Kong. His main interest of research is clinical and translational studies on hepatobiliary-pancreatic and neuroendocrine cancers. Prof. Chan has published over 200 papers in peer reviewer journals and delivered over 140 international lectures.

Internationally, Prof. Chan is serving as the Head of External Relations of the International Liver Cancer Association (ILCA). He has also served in Scientific Committee of the European Society for Medical Oncology Congress as a track chair in 2021 and committee member from 2022-2023. Besides, He has been invited to be Associate Editors in several journals including Journal of Hepatology, Liver Cancer, and Therapeutic Advances in Medical Oncology.

Locally, Prof. Chan is the Panel Member of Biology and Medicine Panel for the General Research Fund in Hong Kong. He has also established a charity hand in hand cancer foundation to serve patients in need.

Speciality

Associate Professor, Icahn School of Medicine Mt Sinai

Personal Information

Amaia Lujambio got her PhD at the Spanish National Cancer Center (CNIO) studying the epigenetic regulation of microRNAs in cancer (Esteller laboratory). She then pursued her postdoctoral studies (Scott Lowelaboratory) demonstrating that p53 can suppress liver tumorigenesis through non-cell-autonomous mechanisms by modulating macrophage polarization and tumor microenvironment, highlighting the importance that the immune cell compartment has in liver cancer. The focus of the Lujambio laboratory is to better understand liver cancer initiation and liver cancer maintenance by using sophisticated mouse models of cancer, RNA interference and CRISPR technology, valuable human samples, and genetic and immune profiling as key tools.

Speciality

Abdominal Transplant & HPB Surgical Oncology, University Health Network….

Personal Information

Dr. Gonzalo Sapisochin is Staff Surgeon at The Toronto General Hospital, UHN. Dr. Sapisochin received his Medical Diploma in 2005 from the Universidad Complutense de Madrid, Spain and went on to complete his General Surgery residency training in 2011 at the University Hospital of Vall d’Hebron in Barcelona where he successfully defended his Doctoral Thesis, “Optimization of Liver Transplantation for Hepatocellular Carcinoma”, to receive his PhD be the Universidad Autonoma de Barcelona. He went on to complete his Clinical Fellowship in Abdominal Transplant & HPB Surgical Oncology with the University of Toronto and was subsequently recruited in a position at the Toronto General Hospital as Staff Surgeon with the Multi-Organ Transplant Program and the Division of General Surgery. He is currently an Associate Professor of Surgery at the University of Toronto. Dr. Sapisochin main research interest is the “interface” between liver transplantation and cancer. He has been one of the drivers of the concept of Transplant Oncology and chaired in 2019 the ILTS Consensus Conference in this topic. He has focused his research in the management of hepatocellular carcinoma, cholangiocarcinoma and colorectal liver metastases. He has published more than 150 original manuscripts in peer-reviewed journals such as Journal of Hepatology, Hepatology, Annals of Surgical Oncology or Annals of Surgery.

Speciality

Associate Professor of Medicine, University of Chicago Medicine

Personal Information

Anjana Pillai, MD, is an Associate Professor of Medicine at the University of Chicago Medicine and a board-certified gastroenterologist and transplant hepatologist who specializes in the management of chronic liver disease and hepatobiliary malignancies. Dr. Pillai is the medical director of University of Chicago’s multidisciplinary liver tumor program, the medical director of the Adult Living Donor Liver Transplant Program and the Program Director for the ACGME accredited Transplant Hepatology Fellowship.  In 2019, she co-founded the HCC Therapeutics Targets Conference (HCC-TAG), which is geared towards bringing clinicians and researchers in academia and the pharmaceutical industry for a focused interactive educational update on the most relevant advances and challenges in the diagnosis and therapy of HCC.  Dr. Pillai is also active in national societies serving on several committees of the American Society of Transplantation (AST), American Association for the Study of Liver Diseases, American Gastroenterology Association and the American College of Gastroenterology over the years. She has served on the United Network for Organ Sharing (UNOS) Regional Review Board, and now sits on the UNOS National Liver Review Board. She is the current Chair of the AST Liver and Intestinal Community of Practice (LICOP) Executive Committee. She is personally committed to promoting the career advancement and development of leadership skills for trainees and especially excited to promote women in science and medicine.